2021
Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study
Jacobs R, Jurczak W, Flinn I, Grosicki S, Giannopoulos K, Wróbel T, Zafar S, Cultrera J, Kambhampati S, Danilov A, Burke J, Goldschmidt J, Beach D, Huntington S, Ibarz J, Sharman J, Siddiqi T, Brander D, Shadman M, Pagel J, Dlugosz-Danecka M, Ghosh N, Kolibaba K, Sportelli P, Miskin H, O'Connor O, Weiss M, Gribben J. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study. Blood 2021, 138: 3726. DOI: 10.1182/blood-2021-147460.Peer-Reviewed Original ResearchSarah Cannon Research InstituteProgression-free survivalOverall response rateChronic lymphocytic leukemiaCurrent equity holderMedian progression-free survivalUndetectable minimal residual diseaseNon-infectious colitisBristol-Myers SquibbTreatment-naïveTN patientsTreatment statusAstra ZenecaSpeakers bureauKite PharmaPFS ratesMedian durationStudy drugMedian agePT patientsADC therapeuticsDay 1Primary analysisEnhanced antibody-dependent cellular cytotoxicityAntibody-dependent cellular cytotoxicity
2020
Worldwide Examination of Patients with CLL Hospitalized for COVID-19
Roeker L, Scarfo L, Chatzikonstantinou T, Abrisqueta P, Eyre T, Cordoba R, Prat A, Villacampa G, Leslie L, Koropsak M, Quaresmini G, Allan J, Furman R, Bhavsar E, Pagel J, Hernandez-Rivas J, Patel K, Motta M, Bailey N, Miras F, Lamanna N, Alonso R, Osorio-Prendes S, Vitale C, Kamdar M, Baltasar P, Österborg A, Hanson L, Baile M, Rodríguez-Hernández I, Valenciano S, Popov V, Garcia A, Alfayate A, Oliveira A, Eichhorst B, Quaglia F, Reda G, Jimenez J, Varettoni M, Marchetti M, Romero P, Grau R, Munir T, Zabalza A, Janssens A, Niemann C, Perini G, Delgado J, San Segundo L, Roncero M, Wilson M, Patten P, Marasca R, Iyengar S, Seddon A, Torres A, Ferrari A, Cuéllar-García C, Wojenski D, El-Sharkawi D, Itchaki G, Parry H, Mateos-Mazón J, Martinez-Calle N, Ma S, Naya D, Van Der Spek E, Seymour E, Vázquez E, Rigolin G, Mauro F, Walter H, Labrador J, De Paoli L, Laurenti L, Ruiz E, Levin M, Šimkovič M, Špaček M, Andreu R, Walewska R, Perez-Gonzalez S, Sundaram S, Wiestner A, Cuesta A, Broom A, Kater A, Muiña B, Velasquez C, Ujjani C, Seri C, Antic D, Bron D, Vandenberghe E, Chong E, Lista E, García F, Del Poeta G, Ahn I, Pu J, Brown J, Campos J, Malerba L, Trentin L, Orsucci L, Farina L, Villalon L, Vidal M, Sanchez M, Terol M, De Paolis M, Gentile M, Davids M, Shadman M, Yassin M, Foglietta M, Jaksic O, Sportoletti P, Barr P, Ramos R, Santiago R, Ruchlemer R, Kersting S, Huntington S, Herold T, Herishanu Y, Thompson M, Lebowitz S, Ryan C, Jacobs R, Portell C, Isaac K, Rambaldi A, Nabhan C, Brander D, Montserrat E, Rossi G, Garcia-Marco J, Coscia M, Malakhov N, Fernandez-Escalada N, Skånland S, Coombs C, Ghione P, Schuster S, Foà R, Cuneo A, Bosch F, Stamatopoulos K, Ghia P, Mato A, Patel M. Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood 2020, 136: 45-49. PMCID: PMC8330255, DOI: 10.1182/blood-2020-136408.Peer-Reviewed Original ResearchCase fatality rateInferior overall survivalOverall survivalCOVID-19 diagnosisAstra ZenecaMultivariable analysisSpeaker feesSeattle GeneticsSpeakers bureauAbbVie IncSanofi GenzymeBaseline characteristicsIndependent predictorsF. Hoffmann-La RocheJanssen-CilagCOVID-19ADC therapeuticsStandardized case report formAdvisory CommitteeEducational meetingsHoffmann-La RocheF. Hoffmann-La Roche LtdAdvanced patient ageSevere COVID-19Kaplan-Meier methodCNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions
Orellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romancik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Prete C, Olszewski A, Ayers E, Landsburg D, Echalier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens D, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portell C. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. Blood 2020, 136: 27-28. DOI: 10.1182/blood-2020-134798.Peer-Reviewed Original ResearchAggressive non-Hodgkin lymphomaNon-Hodgkin lymphomaGenentech/RocheDouble-hit lymphomaCNS-IPIAstra ZenecaSeattle GeneticsBristol-Myers SquibbSpeakers bureauElevated LDHRituximab eraHIV statusUS academic institutionsADC therapeuticsB cellsSignificant differencesMedian age 61 yearsIndolent non-Hodgkin lymphomaAdvisory CommitteeHigh-grade B-cellDiffuse large B-cellAnthracycline-based therapyECOG PS 0Recipients of chemotherapyAge 61 years
2019
AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Huntington S, Kallam A, Basile F, Ulanet D, Xu H, Yin F, Mobilia M, Cooper M, Shah B, Leonard J, von Keudell G, Gopal A. AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study. Blood 2019, 134: 1286. DOI: 10.1182/blood-2019-123420.Peer-Reviewed Original ResearchDose-limiting toxicityDiffuse large B-cellDose-escalation phaseAgios PharmaceuticalsAdvanced lymphomaHematologic malignanciesKaryopharm TherapeuticsSeattle GeneticsEscalation phaseT cellsEastern Cooperative Oncology Group performance statusADC therapeuticsActive central nervous system diseaseAdaptive Bayesian logistic regression modelChimeric antigen receptor T-cell therapyPrior stem cell transplantSerum total bilirubin levelPhase 1 clinical studyCentral nervous system diseaseDose-expansion phaseOptimal starting doseCycles of therapyOpen-label studyAbsolute neutrophil countAdvanced solid tumors